KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

KALV

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/31

07:20 am

kalv

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]

Low Report

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]

Report

3/31

07:00 am

kalv

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

Medium Report

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

Report

3/26

11:41 am

kalv

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.

Low Report

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.

Report

3/26

09:03 am

kalv

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Jones Trading. They now have a $30.00 price target on the stock.

Low Report

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Jones Trading. They now have a $30.00 price target on the stock.

Report

3/25

08:00 am

kalv

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial [Yahoo! Finance]

Medium Report

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial [Yahoo! Finance]

Report

3/25

07:00 am

kalv

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Low Report

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Report

3/14

08:36 am

kalv

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Low Report

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Report

3/13

08:00 am

kalv

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.

Medium Report

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.

Report

3/12

07:00 am

kalv

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Low Report

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Report

3/10

07:00 am

kalv

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Medium Report

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Report

3/4

07:00 am

kalv

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Medium Report

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Report

3/3

07:07 am

kalv

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting [Yahoo! Finance]

Medium Report

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting [Yahoo! Finance]

Report

3/3

07:00 am

kalv

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Medium Report

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Report

2/24

07:12 am

kalv

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences [Yahoo! Finance]

Medium Report

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences [Yahoo! Finance]

Report

2/24

07:00 am

kalv

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Medium Report

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Report

2/21

07:32 am

kalv

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting [Yahoo! Finance]

Medium Report

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting [Yahoo! Finance]

Report

2/21

07:00 am

kalv

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Low Report

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Report

2/10

07:18 am

kalv

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting [Yahoo! Finance]

Low Report

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting [Yahoo! Finance]

Report

2/10

07:00 am

kalv

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

Low Report

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

Report

2/4

07:00 am

kalv

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Low Report

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Report

2/1

05:58 am

kalv

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.

Low Report

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) was upgraded by analysts at Citizens Jmp to a "strong-buy" rating.

Report

1/31

02:38 pm

kalv

KalVista Pharmaceuticals initiated with Market Outperform rating at JMP [Seeking Alpha]

Low Report

KalVista Pharmaceuticals initiated with Market Outperform rating at JMP [Seeking Alpha]

Report

1/31

07:33 am

kalv

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $19.00 price target on the stock.

Low Report

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $19.00 price target on the stock.

Report

1/21

07:19 am

kalv

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema [Yahoo! Finance]

Medium Report

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema [Yahoo! Finance]

Report

1/21

07:00 am

kalv

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

Medium Report

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.